Archives
Network Pharmacology Reveals SFI Inhibits Glioma via SRC/PI3
2026-08-06
Network Pharmacology Reveals SFI Inhibits Glioma via SRC/PI3K/AKT Signaling
Study Background and Research Question
Glioma, a highly invasive and rapidly proliferating primary brain tumor, continues to pose severe clinical challenges due to poor prognosis and limited therapeutic efficacy. Despite advances in surgery, radiation, and chemotherapy, median survival remains under 17 months for glioblastoma patients. There is an urgent need for new therapeutic avenues, particularly those capable of targeting core mechanisms of glioma proliferation and migration. Traditional Chinese medicines, including Shenqi Fuzheng injection (SFI), have been used as adjuncts in cancer therapy, but their precise molecular mechanisms against glioma have remained largely unexplored. The central research question addressed by Li et al. (2024) is: What are the molecular targets and pathways through which SFI acts to inhibit glioma progression?Key Innovation from the Reference Study
The innovation of this study lies in its integration of network pharmacology with experimental validation to dissect the multi-target and multi-component nature of SFI in the context of glioma. Rather than focusing on single-target interventions, the authors employed a systems approach to map the interaction landscape between SFI's bioactive constituents and glioma-associated molecular pathways. This led to the identification of the SRC/PI3K/AKT signaling axis as a pivotal mediator of SFI's anti-glioma effects, a finding that bridges computational predictions with laboratory findings.Methods and Experimental Design Insights
The study is notable for combining in silico network pharmacology with robust cellular and animal model validation:- Target Screening: SFI’s active compounds and their predicted targets were cross-referenced with known glioma-related targets using curated databases and literature mining. A total of 26 major SFI components and 3,343 glioma-associated targets were identified, with 79 shared targets.
- In Vitro Assays: Human glioma cell lines (U87, T98G) were treated with SFI and analyzed for proliferation (CCK-8 assay, EdU incorporation), colony formation, migration (scratch and Transwell assays), cell cycle distribution (flow cytometry), and expression of epithelial-mesenchymal transition (EMT) markers and pathway proteins (immunofluorescence, western blot).
- In Vivo Model: A subcutaneous tumor model was established by implanting GL261 glioma cells in C57BL/6 mice. Tumor growth inhibition was assessed by histological (HE) staining and immunohistochemistry.
- Network Analysis: Pathway enrichment and protein–protein interaction analyses pinpointed SRC/PI3K/AKT as a critical pathway modulated by SFI treatment.
Protocol Parameters
- SFI in vitro dosing: SFI concentrations were titrated to assess dose-dependent effects on U87 and T98G cell proliferation and migration.
- Cell cycle analysis: Flow cytometry was used after SFI treatment to determine S-phase arrest and cell population shifts.
- In vivo tumor model: Subcutaneous injection of GL261 cells in C57BL/6 mice, followed by SFI administration; tumor size and histopathology assessed at defined endpoints.
- Pathway evaluation: Western blot and immunofluorescence to quantify SRC, PI3K, AKT, and EMT marker proteins post-SFI treatment.
Core Findings and Why They Matter
The study demonstrated that SFI effectively inhibits glioma cell proliferation and migration in vitro, induces S-phase cell cycle arrest, and downregulates EMT markers, thereby limiting tumor cell invasiveness. In vivo, SFI treatment significantly suppressed tumor growth in the GL261 mouse model. Mechanistically, both network pharmacology and experimental data converge on the SRC/PI3K/AKT pathway, indicating that SFI’s multi-component nature exerts a concerted blockade along this axis. This mechanistic insight is significant as the SRC/PI3K/AKT pathway is known to drive oncogenic processes including cell survival, migration, and angiogenesis, suggesting broader applications in anti-angiogenic and anti-metastatic research (reference).Comparison with Existing Internal Articles
Several internal resources provide context for the translational and methodological relevance of this work:- The article "Network Pharmacology Reveals SFI Blocks Glioma via SRC/PI3K/AKT Pathway" offers a complementary summary, reinforcing the centrality of SRC/PI3K/AKT in SFI-mediated glioma suppression and providing additional workflow details for anti-angiogenic studies.
- Internal reviews such as "AAL-993 in Tumor Angiogenesis: Mechanistic Insights & Translational Impact" and "AAL-993: Advancing Tumor Angiogenesis Research with Selective VEGF Inhibition" highlight the value of precise VEGF receptor inhibitors in dissecting angiogenesis within tumor models. These resources underscore the intersection of network pharmacology with selective pharmacological tools for anti-angiogenic compound evaluation.
Limitations and Transferability
While the integrated network and experimental approach provides robust evidence for SFI’s action via SRC/PI3K/AKT, several limitations merit consideration:- Complexity of Herbal Formulations: The multi-component nature of SFI means that attribution of effects to individual compounds remains challenging; synergistic or antagonistic interactions are not fully resolved.
- Model Specificity: The cellular and animal models used (U87, T98G, GL261) may not capture the full heterogeneity of human gliomas.
- Pathway Breadth: While SRC/PI3K/AKT is highlighted, network pharmacology also suggests potential involvement of additional signaling cascades that were not deeply investigated here.
- Clinical Translation: Although SFI is used clinically as an adjunct, the mechanistic findings await validation in human trials and broader tumor contexts.